You are here

Articles

CML management at the time of the COVID-19 pandemic in Italy.

published: 22 June 2020

COVID-19 in persons with chronic myeloid leukaemia

published: 4 June 2020

Join the COVID Symptom Study

published: 11 April 2020

iCMLf FAQ: CML, TKI treatment and COVID-19 disease-

published: 3 April 2020

Recommendation from the NCRI CML Subgroup- updated 27th March 2020

published: 23 March 2020

Public Health England - COVID-19 Guidance Document

published: 22 March 2020

CML and COVID-19 case collection by iCMLf

published: 19 March 2020

Guidance from iCMLf regarding COVID-19

published: 10 March 2020

European LeukemiaNet 2020 recommendations for treating CML

published: 4 March 2020

NCCN 2020 QUICK GUIDE - Guidelines for CML Patients

published: 28 February 2020

Update: An investigation into the use of app technology in patients with CML

published: 19 February 2020

Managing CML for treatment-free remission (TFR): A proposal - GIMEMA CML WP

published: 3 February 2020

Ruxolitinib Shows Noteworthy Responses in Patients with Atypical CML

published: 14 January 2020

Do persons with chronic myeloid leukaemia have normal or near normal survival?

published: 6 January 2020

An investigation into the use of app technology in patients with CML.

published: 5 November 2019

Cessation of nilotinib in patients with CML who have kept deep molecular responses for 2yrs

published: 3 October 2019

Combining Asciminib with Ponatinib Suppresses Emergence Highly Resistant BCR-ABL1 Mutants

published: 3 October 2019

Long‐term follow‐up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic CML

published: 3 October 2019

CML: the concepts of resistance and persistence and the relationship with BCR-ABL1

published: 3 October 2019

Cortes Highlights Second-Generation TKIs for Frontline Therapy in CML

published: 9 August 2019